These problems can be best addressed by systematic studies of antigen three-dimensional structure and further ... the production of a recombinant hepatitis B virus (HBV) vaccine 3.

Total Revenue of $426.5 Million, a 65% YoY IncreaseFY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation ...

Maternal hepatitis C virus (HCV) RNA titer > 10⁶ International Units (IU)/mL and antepartum bleeding are key predictors of ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Insect miRNAs can be transferred to their host plants upon feeding. This study shows that a conserved insect microRNA plays a ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and ...

a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also ...

Hepatitis B virus (HBV) infection is still a serious public health problem worldwide. Antiviral therapies such as interferon and nucleos(t)ide analogs efficiently control HBV replication, but they ...

Feb. 26, 2025 — Scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by reprogramming aggressive cancer cells into harmless ..